VPCI Pioneers 'Virtual GMP Consulting' for FDA Pharmaceutical Manufacturers

VPCI Pioneers 'Virtual GMP Consulting' for FDA Pharmaceutical Manufacturers
MIAMI, Feb. 16 /PRNewswire/ -- Pharmaceutical manufacturers around the world now have access to high-level, FDA support services at the touch of a button.  VPCI (Vectech Pharmaceutical Consultants International) has pioneered a "Virtual GMP Consulting" service.  Through the use of high definition video conferencing equipment and collaboration software, Pharmaceutical manufacturers now have access to GMP consultation services on-demand, and at a fraction of the cost.

In today's Pharmaceutical industry, FDA support services through telephone and e-mail are not enough.  Face-to-face meetings and discussions are vital for success, but travel is expensive and time-consuming.  The "Virtual GMP Consulting" service allows a client to maximize productivity by eliminating wasted travel time and expenses.  Access to high-level, GMP support services can now be as quick and easy as pressing a few buttons.

"VPCI has always been a technology-focused, GMP services company," said Franco DeVecchi, Chairman of VPCI.  "Our clients operate in a very technical, FDA-regulated environment and we have always looked for new ways to help them.  With the Pharmaceutical industry becoming more global, and especially during tough economic times, manufacturers need support services that are both cost-effective and time sensitive.  We believe that our 'Virtual GMP Consulting' service will produce huge benefits for its users by allowing quick access to some of the industry's most highly skilled consultants." 

About VPCI

VPCI, Inc. (Vectech Pharmaceutical Consultants International) (www.vpcint.com) is a Pharmaceutical consulting company offering FDA regulatory guidance, manufacturing technology support and high-level business development services.  With scientific and technical experts on a global scale, VPCI has the ability to communicate with clients and regulatory agencies in a number of languages, strictly following good manufacturing practices (GMP).


SOURCE VPCI, Inc.

RELATED LINKS
http://www.vpcint.com

Suggested Articles

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.

Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180 million in cash.